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ABSTRACT 
BACKGROUND: 
Natural killer cells play an important role in the innate and adaptive 
immune system. The immune defense against tumour cells is mainly mediated by 
the natural killer cells. Cluster of differentiation 57 is a 110-kd glycoprotein, 
typically expressed by the natural killer cells, attack the cancer cells and inhibit 
the tumour development. Proliferating cell nuclear antigen (PCNA) is a 36 kd 
auxiliary protein for DNA polymerase delta, located on chromosome 20p12 
correlates with the cell proliferation and DNA synthesis. This PCNA protein 
varies during cell cycle and accumulates in late G and S phase of the cell cycle. 
PCNA is essential component of the DNA replication, DNA recombination and 
repair. 
AIMS AND OBJECTIVE:  
To compare and correlate the expression of CD57 and PCNA   in different 
grades of oral squamous cell carcinoma by immunohistochemistry. 
MATERIALS AND METHODS: 
Previously histopathologically confirmed 30 samples of different grades 
of oral squamous cell carcinomas and 10 samples of normal mucosa were 
included in this retrospective study. The histopathological sections were 
examined immunohistochemically for CD57 and PCNA expression. The 
statistical analysis was done by Anova (Post hoc) followed by Dunnet t-test and 
correlation between the markers was done by Pearson correlation test.   
Abstract 
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RESULTS 
                The CD57 expression in oral squamous cell carcinoma was found to be 
higher in well differentiated squamous cell carcinoma and lower in poorly 
differentiated squamous cell carcinoma whereas expression of PCNA was found 
to be lower in well differentiated squamous cell carcinoma and higher in poorly 
differentiated squamous cell carcinoma. 
CONCLUSION: 
                     CD57 expression was found to be decreasing from well 
differentiated squamous cell carcinoma to poorly differentiated squamous cell 
carcinoma. On the other hand, proliferative activity was found to be increasing 
from well differentiated squamous cell carcinoma to poorly differentiated 
squamous cell carcinoma.  Therefore, the combination of CD57 and PCNA 
biomarkers appears to be good indicators of the immune status of the patient and 
the aggressiveness of the lesion. 
Keywords: CD57, Proliferating cell nuclear antigen, Immunohistochemistry, 
Oral squamous cell carcinoma 
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INTRODUCTION 
Cancer is a multistep process with multifactorial etiology that involves 
initiation, promotion and progression of tumour1. At present, cancer is the second 
most common cause of morbidity and mortality in the world next to the 
cardiovascular diseases2. According to GLOBOCAN 2012, annually about 14.1 
million new cancer cases and 8.2 million cancer-related deaths occurs 
worldwide3. In India, as per the study conducted by ICMR in 2016, 14.5 lakhs of 
new cases are added annually and about 7.3 6 lakh people die of these deadly 
diseases every year4. Oral cancer ranks as the sixth most common cancer in the 
world2. In India, oral cancer and breast cancer are the cancers that rank first in 
males and females respectively4. About 90% of the oral cancer reported is of oral 
squamous cell carcinoma.     
Multicellular organisms can sustain their life only when all the cells 
function in accordance with the rules that regulate the cell growth and 
reproduction5. The cell numbers are maintained by controlling the rate of cell 
division as well as death of the cells. Thus, mitosis and apoptosis maintain the 
normal homeostasis of the body. Dysregulation of these mechanisms, may lead to 
either increase or decrease in the cell number. Hence, cancer develops as a disease 
of uncontrolled growth and proliferation whereby the cells escape the normal 
growth, reproductive control mechanisms and undergo limitless cell proliferation6. 
For a normal cell to acquire abnormal function, it requires genetic 
alterations over a longer period of time. These alterations may be due to inherited 
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mutations or by certain environmental factors such as UV rays, X rays, 
chemicals, tobacco products, virus7. The development of cancer is a multistep 
process that requires around four to seven events for the genetic changes to occur. 
These genetic alterations involve the classic hallmarks of malignancy and 
undergo immortalization7. Thus, cancer is referred as a disease of multistep 
process in which the cells undergo metabolic and behavioral changes, leading 
them to proliferate in an extensive and ultimate way7. 
Normal control systems prevent the tumour cells to undergo cellular 
proliferation and differentiation. When these control mechanisms gets altered, 
they undergo cellular proliferation that leads to uncontrolled cell growth even in 
the presence of the signals that normally inhibit cell growth and division5. These 
cancer cells acquire newer characteristics such as changes in cell structure, 
decreased cell adhesion, loss of normal architecture, breakdown of tissue 
boundaries, stromal changes, angiogenesis and invasion and metastasis8.  
Because of these newer characteristics, the cells exhibit uncontrolled proliferation 
and spreads rapidly resulting in invasion and metastasis. These abnormalities in 
the cancer cells are due to mutations in the proto oncogenes, tumour suppressor 
genes and DNA repair genes5. 
Regarding the incidence of the disease, there is a large amount of 
disparity exists between the developed and under developed countries. The 
incidence of the disease is higher in developed countries while the mortality rate 
is higher in under developed countries due to the lack of early diagnosis and the 
facilities of the treatment is poor in that countries3.  In spite of the newer multi 
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therapeutic treatment modalities, the overall survival rate of oral squamous cell 
carcinoma is still questionable. Invariably, early detection of the disease provides 
better survival rate6. The development of molecular biological techniques may be 
helpful in detecting the early diagnosis of tumours and also to identify newer 
method to inhibit the growth of cancer that pave the way for more selective, less 
toxic, non-invasive forms of chemotherapy9. Biomarkers, that can act as indicators 
of the aggressiveness and recurrence of the lesion are useful in such case5. 
Natural killer cells (NK) play an important role in the innate and adaptive 
immune system. The immune defense against tumour cells is mainly mediated by 
the NK cells2. These cells detect and limit the development of the tumour directly 
without any priming or prior activation9. Natural killer cells identify the tumour 
cells by the lack of expression of major histocompatibility complex – I and 
secretes cytokines like interferon – gamma and tumour necrosis factor- α2. 
CD57 was identified on natural killer cells by using the mouse 
monoclonal antibodies Human Natural Killer-1 (HNK1). It was designated as 
cluster of differentiation, CD57 in 1989 by the fourth International Workshop of 
Human Leukocyte Antigens10,11. CD57 (cluster of differentiation 57) is a 110-kd 
glycoprotein which is typically expressed by the NK cells, attack the cancer cells 
and inhibit the tumour development9. 
Proliferating cell nuclear antigen (PCNA - Cyclin) is a 36 kd auxiliary 
protein for DNA polymerase delta, located on chromosome 20p12 correlates with 
the cell proliferation and DNA synthesis. This PCNA protein varies during cell 
cycle and accumulates in late G and S phase of the cell cycle12. This protein is 
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increased in the G1 and S phase and it is decreased in the G2 phase. Hence, this 
protein is a reliable indicator of cell proliferation13. PCNA is an essential 
component of the DNA replication, DNA recombination and repair.The 
malignant tissue is also characterized by an uncoordinated proliferation of this 
antigen namely, PCNA14. 
Since cellular proliferation and the presence of NK cells are important 
indicators for the aggressive nature and prognosis of the disease, these 
biomarkers are useful in predicting the aggressiveness of the disease as well as 
the immune status of the individual12 and so this study aims to use CD57 and 
PCNA biomarkers to determine the immune status as well as aggressiveness or 
the biologic behavior of the disease thereby helping in planning of the treatment. 
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AIMS AND OBJECTIVES 
AIM: 
  To compare and correlate the expression of CD57 and PCNA in different 
grades of oral squamous cell carcinoma by immunohistochemistry. 
OBJECTIVES:  
Primary Objective: 
 Comparison and correlation of CD57 and PCNA expression in different 
grades of oral squamous cell carcinoma and also with that of control group. 
Secondary Objective 
 To evaluate the expression of CD57 and PCNA in different grades of oral 
squamous cell carcinoma 
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REVIEW OF LITERATURE 
Oral squamous cell carcinoma, also called as oral cancer is the utmost 
frequently occurring malignant tumour in the oral cavity.15, 16. Oral squamous cell 
carcinoma is defined as a malignant neoplasm of epithelial tissue with invasive 
behavior and variable degree of differentiation with or without keratinization17. 
Oral cancer is a multifactorial and a multistep process in which the cells undergo 
genetic mutation leading to proliferation of cells enormously and disregarding the 
rules of normal cell division18.  Thus, oral cancer is the second most cause of 
mortality and morbidity in the world. 
ANATOMY AND PHYSIOLOGY OF ORAL CAVITY: 
The oral cavity arises from the lips externally and terminates to the 
junction of the hard and soft palate internally. It is surrounded anterolateraly by 
the gums, teeth and the alveolar arches of the jaws. The roof is formed by the 
hard palate and the soft palate while the floor of the oral cavity is formed by the 
tongue posteriorly and the sublingual region, anteriorly. Posteriorly, it 
communicates with the pharynx by the isthumus of fauces19. 
INCIDENCE AND PREVALENCE: 
The incidence rate of oral cancer is highest in southern and Southeast Asian 
countries which constitutes a major health issues in these regions. According to 
WHO, oral cancer is considered to be the sixth most common cancer in males and 
in females, it is the tenth most common cancer in developing countries20. The 
international agency for research on cancer (IARC) in India estimated that  the 
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incidence rate of oral cancer increases  from 1 million in 2012 to more than  1 .7 
million  in 2035 and the death rate  will also increases from 680000 in 2012  to 1-2 
million in 203521. 
According to the studies conducted by the urban and rural registries,  oral 
cancer is more commonly seen in the northern part of India especially states like 
Uttar Pradesh because of the use of smokeless tobacco. Oral cancer is more 
common in western regions of the country among the males and east Khasi hills 
of Meghalaya records the highest number of oral cancer cases among females. 
Among the cancers about 30% accounts for the tobacco related cancers21. 
ETIOLOGY: 
In India, the oral cancer is due to a number of etiological factors. Tobacco 
consumption either in the form of smoking and smokeless tobacco, alcohol 
consumptions, chewing betel quid with areca nut are the major risk factors in the 
pathogenesis of oral cancer in India. Viruses, immunosuppression, occupational 
risks, radiation, familial and genetic susceptibility are the other common causes of 
oral cancer. 
Epigenetic factors  
a. Tobacco   
In India and other Asian countries, chewing tobacco with betel quid is the 
main causative agent in oral cancer. About 90 % of the oral cancers are caused by 
tobacco products. Various forms of tobacco are smokeless tobacco (Gutka, Paan, 
Zarda, Mawa, Kharra and Khaini), Betel quid, Cigarettes, Bidi & pipe smoking 
and Hookah) 22. 
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Tobacco smoke contains benzo-pyrene, tobacco- specific nitrosamines, 
arsenic and benzene.  These products react with the DNA of keratinocytes and 
causes mutation in the DNA replication. In addition, tobacco pro-carcinogens are 
being metabolized by oxidizing enzymes like cytochrome P450 to promote the 
destruction and to counteract the protective effects of glutathione S- transferase, 
glutathione reductase and superoxide dismutase 23. 
Marijuana, which is also called as bhang or ganja is used as smoking 
cigarettes. Tobacco which forms a part of the smoke contains potent carcinogen 
that predisposes to oral cancer formation 24. 
Smokeless tobacco is used either as a dry snuff or wet snuff. Wet snuff is 
more common in north-western regions of India. Smokeless tobacco is kept 
inside the oral cavity where it contacts with the mucous membrane and the 
nicotine is absorbed by the mucosa which further leads to oral cancer 25. 
b. Betel quid  
In the Indian subcontinent, chewing betel quid is the most common and 
prevalent habit. Betel quid usually contains betel leaf, slaked lime, areca nut, and 
tobacco. Other ingredients such as cloves, cardamom or aniseed are also added to 
the quid in India and turmeric in Thailand26. Chewing betel nut alone is also said 
to be carcinogenic. The association of all these products develops precancerous 
lesions such as erythroplakia, leukoplakia, and oral submucous fibrosis. Betel 
quid chewing generates reactive oxygen species (ROS) and further induces the 
initiation of tumour 27. 
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c. Alcohol: 
         Alcohol are said to be carcinogenic in tumours of oral cavity, pharynx, 
larynx, oesophagus, and liver. Combination of alcohol and tobacco chewing 
possess an increased risk for oral cancer development than the usage of alcohol 
alone26. N-nitroso compounds, urethane, mycotoxins, inorganic arsenic are the 
carcinogens present in the alcohol. By the enzyme alcohol dehydrogenase (ADH), 
these substances are metabolized to acetaldehyde, which is then oxidized by means 
of aldehyde dehydrogenase (ALDH) to acetate. This acetaldehyde damages the 
DNA, interferes with the DNA synthesis and repair and thus initiates or promotes 
tumour formation. In oral mucosa, rapid oxidation of alcohol to acetaldehyde by 
ADH enzyme occurs and in contrast, acetaldehyde gets accumulated due to 
reduction in ALDH [aldehyde dehydrogenase] enzyme. Thus, genetic changes 
occur by these two enzymes that provides an increased risk of oral cancer 28. 
Due to hepatic damage, the detoxification of carcinogenic substance like 
polycyclic aromatic hydrocarbons and N- nitrosamines are inhibited and thus 
leading to tumour formation. Chronic alcoholics with lack of nutrition are a 
contributory factor in the etiology of oral cancer28. 
d. Diet and nutrition: 
According to IARC, reduced intake of fruits and vegetables may increases 
the risk for oral cancer. Increased intake of carrots, fresh tomatoes and green 
peppers reduces the risk of oral and pharyngeal cancer. The other food products 
like bread, legumes, cereals, vegetable oil, olive oil, fish, fresh meat, chicken, 
liver, shrimp and lobster have a protective effect against cancer29. Micro nutrients 
like vitamins A (retinol), vitamin E (alpha-tocopherol), vitamin C, carotenoids 
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(beta-carotene), selenium and potassium have antioxidant property. These anti-
oxidants reduce the free radical reactions and minimize the genetic mutation29. 
Iron deficiency anemia and the Plummer-Vinson syndrome are associated with an 
increased risk of cancer on the upper respiratory and digestive tract27. 
e. Viral infections: 
Highly oncogenic virus contains viral oncogenes in their genome. Viral 
oncogenes interact with the host genetic material and stimulate the proliferation 
of their host cells, immortalize the host cell facilitating oral carcinoma26. Human 
papilloma virus is the most common virus implicated in oral carcinogenesis. HPV 
are DNA viruses causing benign proliferative lesions such as papilloma, verruca 
vulgaris, condyloma accuminatum, and focal epithelial hyperplasia or Heck’s 
disease. HPVs 16, 18, 31, 33, 35, and 39 are considered to be the highest risk 
types in oral cancer.  Among them, HPV 16 has been identified in more than 90% 
of HPV positive oro-pharyngeal squamous cell carcinoma and oral cancer30. 
The primary mechanism involved in the pathogenesis of HPV related oral 
cancers are due to two major co-proteins such as E6 and E7. The E6 proteins 
binds to p53 and destroy p53 while E7 proteins binds to and destroy 
Retinoblastoma (pRb) gene respectively. This further disrupts the cell cycle with 
loss of control on DNA replication, repair, and apoptosis31. 
f. Fungal infections: 
Studies showed that candidal species particularly candida albicans are known 
to cause oral premalignant lesions. Candida species are true causative agent or a 
secondary process in oral cancer is still in debate.  In the immune compromised 
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individuals, candida infection coexist and provide synergistic action in the 
development of oral cancer26. 
g. Immunosuppression  
Immunosuppressed individuals like HIV infected individuals; organ 
transplant patients are more prone to get oral squamous cell carcinoma26. 
h. Occupational risks: 
Studies have showed that employees of certain occupations are more 
prone to develop oral and nasopharyngeal cancer.  Evidence for increased risk for 
oral cancer are reported among metal workers, electrical workers, plumbers, 
machinists, painters and other individuals who are exposed to metal dusts26. 
i. Radiation: 
Exposure to excessive UV radiation causes actinic chelitis which may transform 
into oral cancer. Exposure to X-ray radiation may cause chromosomal abnormalities. 
Low doses of ionizing radiation will not have any effects in our body. But each 
exposure to radiation builds up in our body and the risk of cancer increases 26. 
j. Syphilis  
Studies shown that syphilis have weak associations with the oral cancer. This 
can be due to the factor that the disease is detected and treated at an early stage26. 
k. Dental hygiene and other factors: 
Poor oral hygiene, prolonged irritation of sharp teeth, dental sepsis are 
thought to be a causative factor in oral cancer. But some studies have shown that 
the oral cancer is due to the presence of coexisting risk factors like smoking and 
alcohol consumption. Several studies have shown that there is inverse 
Review of Literature 
  12 
 
relationship between the oral hygiene and the occurrence of oral squamous cell 
carcinoma. Substantial evidence is needed to prove this hypothesis26, 32. 
l. Potentially malignant disorders: 
Some precancerous lesions or precancerous condition can progress to oral 
squamous cell carcinoma. They are, 33 
• Leukoplakia 
• Proliferative verrucous leukoplakia 
• Erythroplakia 
• Erythroleukoplakia (nodular or verrucous) 
• Lichen planus (mainly the erosive and atrophic type) 
• Submucous fibrosis 
• Actinic cheilitis 
• Sideropenic dysphagia (Plummer-Vinson syndrome) 
• Discoid lupus erythematosis. 
• Dyskeratosis congenital 
PATHOPHYSIOLOGY IN ORAL SQUAMOUS CELL CARCINOMA 
 
Genetic factors or 
chronic exposure to 
environmental 
carcinogens
Damage to individual 
genes or 
chromosomes[genetic 
damage]
Mutation or amplication
of oncogenes occurs/
Inactivation of tumour 
suppressor gene         
Promote cell survival 
and proliferation
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Molecular pathogenesis in oral squamous cell carcinoma: 
Oral cancer develops through sequential events of genetic mutations 
followed by uncontrolled proliferation of cells. A normal cell require about 6-10 
genetic events to become a cancerous cell. These alterations are due to 
inactivation of tumour suppressor genes and activation of oncogenes leading to 
uncontrolled proliferation of cells and cell death. Genetic alterations include point 
mutations, translocations, amplification and deletions. Point mutation is most 
commonly seen in p53 and K-ras. Gene amplifications and translocations are 
seen in malignant neoplasms34, 35. Recently, microsatellite analyses have shown 
that the allelic imbalance of chromosomal 9p is the most common mutation in 
head and neck squamous cell carcinoma 35. 
The loss of heterozygosity (LOH) is a common genetic mechanism in 
cancer formation, whereby one allele is lost. This clearly indicates the absence of 
functional tumour suppressor gene in the lost region. The remaining recessive 
copy of the tumour suppressor gene can be inactivated by a point mutation, 
thereby leaving no tumor suppressor gene to protect the body. Loss of 
heterozygosity (LOH) was noted in the chromosome 9p21–p22 and in 72% of 
tumours. In precancerous lesions, allelic loss of 3p and 9p region that contain 
tumour suppressor genes are reported whereas LOH at chromosome 3p are seen 
more commonly in recurrent dysplastic lesions. Recent studies showed that about 
77% of premalignant lesions having allelic loss defect, developed oral squamous 
cell carcinoma within five years34. 
Cyclin dependent kinase (CDK), cyclins and cyclin dependent kinase 
inhibitors are the regulators of cell cycle process. p16 is a protein that binds to 
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pRb [retinoblastoma protein] and inhibits the phosphorylation pRb with cyclin 
dependant kinase (CDK) inhibitors, CDK4 and CDK6. Mutation of the CDK 
inhibitors leads to dysregulation of p16 protein and this mutation is more 
commonly seen in oral premalignant lesions. Mutations of cyclin D, cyclin A, 
cyclin B lead to dysregulation of cell cycle process resulting in increased 
proliferation of cells36. 
a) Oncogenes: 
Oncogenes are basically growth promoting genes and mutations in these 
genes either leads to increased function or overproduction of proteins. These 
oncogenes cause cellular alterations and are important initiators in the process of 
early changes of oral cancer. Several oncogenes are implicated in oral 
carcinogenesis35. They are listed as follows: 
a. Abnormal expression of proto-oncogene epidermal growth factor 
receptor (EGFR) 
b. Mutation of the c-myc oncogene 
c. Mutation of the ras family  
d. Bcl-1 gene 
e. PRAD 1/cyclin  D1 gene 
In the early events of oral cancer, deregulation of growth factors and 
increased production of transforming growth factor-alpha (TGF-alpha) is seen. 
This TGF-alpha binds with the EGFR and stimulates cell proliferation. This 
TGF-alpha stimulates angiogenesis in later stage.  Due to the increased 
production of TGF-alpha and epidermal growth factor (EGF), there will be 
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aberrant expression of EGFR. The interaction of TGF-alpha and EGF with the 
EGFR result in a cascade of events triggering the intrinsic pathway. Mutations of 
the EGFR send continuous growth stimulatory signals to the members of the ras 
oncogenes which is located inside the cell37. 
The ras onco-protein is present on the internal aspect of the cell 
membrane and transmits EGFR stimulatory signal to the nucleus. ras binds with 
guanosine diphosphate (GDP) and remains in the inactive state. When the cells 
are stimulated by the EGF and TGF-alpha, the ras oncogene gets activated. This 
activation is achieved by exchanging GDP for guanosine triphosphate (GTP). 
This activated ras protein will in-turn activates the raf protein, MEK, MAPK 
cytoplasmic kinases. Once the raf protein is activated by the enzyme guanosine 
triphosphatase (GTPase), the GTP gets hydrolyzed back to GDP.  The active ras 
protein then return back to its inactive form.  Thus the ras proteins remain active 
only for a limited period of time and regulate the cell proliferation. However, 
mutation of the ras protein, causes the ras gene to remain in its active form and 
sends continuous proliferative signals to the raf protein even without the binding 
of EGFR with the EGF38. 
c-myc gene induces both apoptosis and cell proliferation. c-myc induces 
apoptosis through tumour suppressor gene p53. Increased c-myc activates the 
transcription of cyclin D which further stimulates the cyclin-dependent kinase 
(CDK) enzyme. Active CDK inturn catalyzes the phosphorylation of the 
retinoblastoma tumour suppressor protein (pRb).Thus; on phosphorylation of 
retinoblastoma protein [pRb6], c-myc induces cell proliferation. Thus, c-myc 
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protein is overexpressed in all grades of OSCC due to gene amplification 34.The 
PRAD-1 gene is located on the chromosome 11q13 which encodes a protein 
called cyclin D. This cyclin D together with the Rb gene protein controls the G1 
to S transition of the cell cycle. Amplification of PRAD-1 is associated with 
infiltrative growth pattern and metastases 39. 
            Normally bcl-2 is a protein that inhibits the apoptotic cell death. Tumour 
suppressor gene p53 blocks the activity of the bcl-2 gene by stimulating the 
transcription of Bax protein. Thus, the caspse-3 enzyme activity remains 
unchecked and apoptotic process occurs continuously. P53 suppress the bcl-2 
gene transcription and further lead to apoptosis of cells associated with the DNA 
damage. In addition, hyperactive ras protein blocks the bcl -2 activity, thereby 
blocking the cell death and leading to uncontrolled proliferation 38. 
b) Tumour suppressor genes: 
Tumour suppressor genes play a vital role in oral cancer. About 80% of 
the oral cancer is found to be associated with the mutation of tumour suppressor 
gene, p5334, 38. 
Normally, p53 protein detects the DNA damage and prevents the cells 
from entering into the cell cycle. Whenever, there is DNA damage there will be 
an increased expression of p53, in turn will stimulate the transcription of p21. 
This p21 gene inhibits the cyclin dependant kinase (CDK) enzyme and blocks the 
pRb phosphorylation which further prevents the release of E2F transcription 
factors and finally, DNA replication is blocked. Proliferating cell nuclear antigen 
(PCNA) is a protein which encircles and slides along the DNA. p21 protein binds 
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with the proliferating cell nuclear antigen (PCNA)  and inhibit the replication  of 
DNA Thus, p53 gene inhibits DNA replication via p21 and prevents DNA 
damaged cells from entering into the cell cycle 38. 
Mutation of the p53 protein causes the DNA damaged cells to participate 
in the cell cycle and continue to divide and passing onto the next generation. 
Habits like smoking and tobacco chewing are associated with the p53 mutation in 
oral squamous cell carcinoma. The most common p53 gene mutation is the 
deletion of one allele accompanied by mutation of other allele 38. 
As a summary, oral cancer results from the oral keratinocytes by three 
mutation of p53 gene which is depicted as a flow chart below: 
Carcinogens like smoking, tobacco, betel nut, radiation or other environmental  
Pollutants  
 
First mutation                  Inactivation one allele of p53 gene 
 
   Second mutation              Inactivation the other allele of p53 gene 
 
Third mutation                Activation of the ras oncogene 
 
c) Cell adhesion molecules: 
         E-cadherin is a cell adhesion molecule involved in invasion and 
metastasis. This protein is down-regulated in most of the oral cancers. Integrin is 
another cell adhesion molecule which mediates cell-cell adhesion and cell –
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matrix interactions. Integrin plays a crucial role in the maintenance of tissue 
integrity, regulation of cell proliferation, differentiation and migration. Integrin 
expression is implicated in the tumour progression and metastasis40. 
In poorly differentiated squamous cell carcinoma, there is decreased 
expression of β1 integrin or α6β4 integrin suggesting that it is an early but 
nonspecific biomarker in oral malignancy. In metastatic oral carcinoma there is a 
strong expression of α2-6 integrins which significantly correlates with the mode 
of tumour invasion41,42. 
Metastasis is not an early event in carcinogenesis. However, because of 
the delay in diagnosis, invasion and metastasis are the major cause of morbidity. 
The alteration in the expression or in the function of the cell adhesion molecules 
indicates the process of tumour infiltration and metastasis34. 
TUMOUR IMMUNOLOGY: 
Tumour immunology is defined as the branch of biology that describes 
the interaction of the host immune cells with the tumour cells and understanding 
the role of the immune system in the progression and the development of 
tumour43. The cells of the immune system identify and destroy the altered or the 
abnormal neoplastic cells thereby inhibiting the development of various tumours. 
Tumour immunology includes three main divisions 
a. Immunosurveillance 
b. Immunoediting 
c. Immune evasion. 
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a) Tumour immunosurveillance: 
The three primary roles of the immune system in the prevention of 
tumours are given below: 
i. Elimination or inhibition of viral infection by host immune cells in viral 
induced tumours. 
ii. Eradication of the pathogens and complete resolution of the inflammation 
will provide an unfavourable environment to carcinogenesis. 
iii. Immune cells detect and destroy the tumour cells by the expression of 
tumour specific antigen. This process is known as immunosurveillance. 
b) Tumour immunoediting: 
It is a process by which the host immune cells reduce the immunogenicity 
of the primary tumour and control the tumour. Thus, cancer immunoediting 
process can promote complete eradication of tumours. This can be accomplished 
by 3E‘s of cancer immunoediting.44 They are 
i. Elimination  
ii. Equilibrium  
iii. Escape. 
i. Elimination:  
   The growing tumour cells in the tissue cause local disruption of tissues 
which alerts the host immune cells.  Because of this local disruption, remodelling 
of stromal cells occurs releasing the proinflammatory chemokines that attracts the 
immune cells to that particular site. The most important immune cells recruited 
are natural killer cells (NK) cells, T- lymphocyte and macrophages. Once these 
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cells are gathered towards the tumour site, natural killer innate immune cells 
identify the tumour cells through the lack of major histocompatibility complex-I 
(MHC-I) expression and release the cytotoxic granules like perforin or 
granzymes causing perforation of the target cells and subsequent cell death45. 
The tumour cells express tumour necrosis factor (TNF) receptor super 
family- like TRAIL receptors, Fas/CD95 and tumour necrosis factor receptor 1 
(TNFRI). NK cells with their corresponding ligands bind with the tumour 
necrosis factor receptor super family (TNFRSF) receptors of cancer cells 
contributing to the cytotoxicity of the cells. In addition, NK cells secrete various 
cytokines and chemokines such as TNF, interferon-gamma (IFN-gamma), MIP-
1a (Macrophage inﬂammatory protein-1a), Granulocyte-macrophage colony 
stimulating factor (GM-CSF), and RANTES (regulated upon activation, normal T 
cell expressed and secreted). Among the cytokines secreted, INF-gamma is 
considered to be crucial in priming the T-helper cells46. NK cells may also 
recognize developing tumours through the interaction T-cell receptor with either 
glycolipid-CD1 complexes or NKG2D ligands expressed on the tumour cells.44. 
Second step:  
Interferon-gamma, released by the NK cells induces the production of 
CXCL (C-X-C motif ligand) -9,10 and 11 from the tumour cells as well as from 
the normal surrounding immune cells of the host, recruit more number of innate 
immune cells to the tumour site47. 
                Interleukin -12 (IL-12) which is released by the macrophages, stimulate 
the NK cells to produce low amount of interferon-gamma. This interferon-gamma 
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further activates the macrophages to release IL-12 which in turn activates the NK 
cells to secrete interferon-gamma. Thus, this cyclic process gets repeated. NK 
cells receptor binds with the NKG2D ligands of the tumour cells and release 
more interferon-gamma. Interferon- gamma activates the process of killing the 
tumour cells by its anti-proliferative, proapoptotic and angiostatic property. 
Activated macrophages release oxygen and nitrogen metabolites that are 
cytotoxic to the cells 47. 
Third step:  
In the third step, the tumour antigens from the dead tumour cells activate 
the dendritic cells. These dendritic cells attracted to the tumour site and get 
activated by two mechanisms: 
a. Innate immune cells secrete the cytokines and the cytokines attract the 
dendritic cell to that site. 
b. By interaction with the NK cells 
        Activated dendritic cells act on the tumour cells either by direct or indirect 
mechanisms. Direct mechanisms involve ingestion of tumour cells directly. 
Indirect mechanisms involve the binding of the tumour antigen to the dendritic 
cell activates the tumour-specific Th1 CD4+ T-cells.  These Th1 CD4+ T-cells 
in-turn activate the cytotoxic CD8+ lymphocytes 48. 
Fourth step:  
Activated Th1 CD4+ T cells and cytotoxic CD8+ lymphocytes involve in 
the process of killing the tumour cells. The Th1 CD4+ T cells produce 
interleukin-2 (IL-2) which along with IL-15 induces the action of cytotoxic CD8+ 
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cells. Activated CD8+ lymphocyte kills the tumour cells either directly or it 
secretes interferon-gamma and promotes cell death.  
Thus, this elimination process is a continuous process and it is repeated   
every time when the neoplastic cells arise. This is because of this reason tumour 
is more prevalent in old age where the immune status of the individual is low 47. 
ii. Equilibrium: 
The cells that have survived from the elimination phase enter into the 
equilibrium phase. This is the longest of all the three phases and occurs over 
many years. The original tumour cells are eliminated in the equilibrium phase but 
due to consequent mutations new tumour cells arise within the tumour site. This 
newly arisen tumour cells are highly resistant to the immune system of the host. 
Therefore, net result of the equilibrium phase is the newer population of tumour 
clones with reduced immunogenicity is seen48. 
iii. Escape: 
Escape phase is the phase that represents the failure of the immune system 
to eliminate or control the transformed cells thereby allowing the tumour cells in 
an uncontrolled manner. Due to the genetic and epigenetic alterations, the tumour 
cells escape from both the innate and the adaptive immune system, thereby 
undergoing uncontrolled proliferation of cells 44. 
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Figure 1:  Three phases of cancer immunoediting 
c) Immune  evasion: 
The ability of the tumour cells to evade the host immune response and is 
capable of uncontrollable growth thereby developing an antitumour response or 
inhibition of host immune functions. In case of an aggressive tumour, the 
aggressive  tumour cells inhibits the functions of the immune cells such as T-
lymphocytes, B-lymphocytes, macrophages, NK cells, Dendritic cells, 
granulocytes and mast cells. Thus the tumour cells hide from the immune system 
and avoid recognition of tumour cells 44. 
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CLINICAL FEATURES: 
Oral squamous cell carcinoma apparently arising in normal mucosa are 
preceded by clinically visible potential malignant disorders like leukoplakia 
(white patch), erythroplakia (red patch), erythroleukoplakia (red and white 
patch), or verrucous leukoplakia. The appearances of these potential malignant 
lesions and the development of oral squamous cell carcinoma may ranges from 
6 months to 39 years 49. 
During the early growth of the lesion, there is minimal pain. Tongue and 
the floor of the mouth are the most common sites for the development of 
intraoral squamous cell carcinoma. Other sites of involvement are buccal 
mucosa, labial mucosa, gingiva, and hard palate. OSCC may manifest as the 
following: 
 A white or mixed white and red lesion 
 A red lesion (erythroplakia) 
 An indurated lump/ulcer (ie, a firm infiltration beneath the mucosa) 
 A granular ulcer with fissuring or raised exophytic margins 
 A lesion fixed to deeper tissues or to overlying skin or mucosa 
 A non-healing extraction socket 
 Cervical lymph node enlargement, especially if hardness is present in a 
lymph node or fixation. Enlarged nodes in a patient with oral carcinoma 
may be caused by infection, reactive hyperplasia secondary to the 
tumor, or metastatic disease. Nodal enlargement is a feature particularly 
in oropharyngeal cancers50. 
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HISTOLOGICAL GRADING OF ORAL SQUAMOUS CELL 
CARCINOMA: 
Many years TNM clinical staging were used, but this system failed to 
clinically estimate the survival as well as the response to the therapy. It was 
Borders’ in 1927 who introduced the quantitative grading of cancer based on the 
proportion of the neoplasm resembling the normal squamous epithelium. Many 
other researchers have also formulated the various grading systems to predict the 
biological behavior of oral squamous cell carcinoma. They are: 
a. Border’s system (1927) 
b. Jakobbson et al (1973) 
c. Fischer et al (1975) 
d. Lund et al  (1975) 
e. Willen et al  (1975) 
f. Crissmann et al (1980) 
g. Anneroth et al (1987) 
h. Bryne’stumour invasive front grading system.(1989,1992)51. 
a) Broder’s (1927) classification:  
Accordingly, tumours were graded as follows: 
Grade I :  Well differentiated tumours - 75-100% of cells are differentiated 
Grade II :  Moderately differentiated tumours - 50-75% of cells are 
differentiated 
Grade III :  Poorly differentiated tumours - 25-50% of cells are differentiated  
Grade IV :  Anaplastic tumour - 0-25% of cells are differentiated52. 
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DIAGNOSTIC TECHNIQUES OF ORAL SQUAMOUS CELL 
CARCINOMA: 
The early identification of the diseases is of paramount important that 
reduce the mortality rate of the diseases. Diagnosis of oral squamous cell 
carcinoma is solely based on the expert clinical examination and histopathological 
examination of the affected area. However, tissue biopsy and histopathological 
examination remains a gold standard technique in the diagnosis of OSCC, the early 
identification of the disease is still remains a challenge. Early identification of the 
disease improves the survival rate as well as reduces the morbidity rate. In order to 
predict the early molecular changes, the introductions of protein biomarkers are of 
significant value 53.The most relevant techniques in the early diagnosis of the 
disease is listed below54: 
VITALSTAINING 
 5% Acetic acid 
 Toluidine Blue 
  Methylene Blue 
 Lugol’s Iodine 
  Rose Bengal 
  Iodine staining 
 Tolonium chloride 
LIGHT BASED DETECTION 
SYSTEMS 
 Tissue fluorescence imaging (Velscope, 
identafi 3000) 
 Chemiluminiscence (ViziLite plus, 
Microlux/DL) 
 Tissue fluorescence spectroscopy  
HISTOLOGICAL 
TECHNIQUES 
 Incisional biopsy 
 Excisional biopsy 
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CYTOLOGICALTECHNIQUES 
 Oral Brush biopsy (Oral CDX) 
 Liquid Based Cytology 
 Laser Microdisection (LCMd) 
MOLECULAR ANALYSES 
 
 Gene alterations 
 Epigenetic alterations, loss of 
Heterozygosity and Microsatellite 
instability 
 Viral genome studies 
 Proliferation index and AgNOR 
Analysis 
 Immunohistochemical identification of 
tumour markers.  
IMAGING TECHNIQUES 
 
 FDG-PET [Fludeoxyglucose (FDG) 
molecule- 
 Optical Coherence Tomography (OCT) 
OTHER TECHNIQUES  Onco-chips 
 
MOLECULAR ANALYSIS BY IMMUNOHISTOCHEMISTRY                
Immunohistochemistry is a technique for identifying the tissue or cellular 
antigens by means of antigen-antibody interactions. The introduction of 
prognostic and predictive biomarkers in immunohistochemistry has made a 
tremendous impact on early diagnosis as well as in the management of the lesion. 
This technique involves the utilization of specific tumour markers to detect 
whether a cancer is benign or malignant or to determine the stage and grade of a 
tumour or to identify the cell type and tumours of unknown histogenesis55. 
Role of tumour markers in oral squamous cell carcinoma: 
When a cell becomes cancerous, newer antigens are expressed on the 
surface.  These are called tumor antigens and the immune system of our body 
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identifies this antigen as foreign material and tries to destroy or eliminate these 
cancerous cells. Sensitive and reliable markers identify this antigen and provide 
information about the forthcoming behavior of an existing cancer. Henceforth, a 
tumour marker is defined as a substance present in or produced by a tumour or by 
the host immune response to the tumour that can be used to distinguish a tumour 
from normal tissue or to detect the presence of a tumour based on the measurement 
in the blood or secretions56. 
Criteria for an ideal tumour marker are57: 
a. It should possess high sensitivity and specificity 
b. It should possess high negative and positive predictive value 
c. It should  have the capability to distinguish the neoplastic  and non-
neoplastic disease 
d. It should be able to predict prognosis and early recurrence of the lesion. 
e. It should be able to identify the tumour at an early stage. 
f. It should be easily assayable 57. 
An ideal tumour marker should possess all these characteristics. The 
tumour markers are useful in various aspects that are listed below56: 
a. Screening process for detecting early malignancy. 
b. As a diagnostic aid for malignancy. 
c. In determining the prognosis of the malignant lesion. 
d. In the prediction for the efficacy of treatment. 
e. In monitoring the therapy in advanced malignancy56. 
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Recently, various tumour biomarkers are identified in the early detection and 
recurrence of oral squamous cell carcinoma. Some of those biomarkers are as follows57: 
a. Albumin 
b. Autoantibodies  
c. Catalase 
d. CD44 
e. CD 59 
f. Neural Wiskott-Aldrich syndrome protein (N-WASP) 
g. Cofilin1[CFL1]  
h. Cancer antigen 125[CA 125] 
i. CYFRA21-1 
j. Endothelins 
k. Glutathione  
l. Interleukin 1α,2β.IL-6,IL-8 
m. Mac-2 binding protein  
n. SCC antigen 
o. S100 antigen 
p. Tissue polypeptide antigen (TPA) 
q. Tumour suppressor gene p53 
r. Telomerase  
s. Tumour necrosis factor-α (TNF-α) 
t. Alpha amylase (α- amylase) 
u. Cell proliferative markers (Cyclin A, B1& D, Proliferating cell nuclear 
antigen-PCNA,  Ki-67) 
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The expressions of these biomarkers in OSCC are helpful in predicting 
the prognosis, patient survival and also with the grading and staging of tumour57. 
Role of CD 57 and PCNA in OSCC: 
Cancer is a process of uncontrolled proliferation and the tumour growth is 
due to the reciprocal interactions of the tumour cells and the stroma in which they 
inhabitat. The infiltration of immune inflammatory cells into the tumour 
microenvironments either promote the progression of tumour or have an 
antitumor effect. Natural killer cells and cytotoxic T-lymphocytes (CD 8+) are 
two potent immune cells exhibiting the antitumor effect. Natural killer cell 
identify the tumour cells by the lack of expression of MHC-I (major 
histocompatibility complex) and kills the tumour cell directly without prior 
sensitization  through the release of interferon-gamma or through perforin-
granzyme enzymes. Hence forth, natural killer cells are important effector cells in 
the control of the disease58. 
CD57(Cluster of differentiation 57) 
Gene profile: 
           Gene                        :   B3GAT1 gene [Galactosyl galactosylxylosyl protein    
                                                    3-    beta - Glucuronosyl transferase 1] 
          Location of the gene:   11q25 chromosomes 
         Function of the gene: A key enzyme in a glucuronyl transfer reaction during 
the biosynthesis of the carbohydrate epitope HNK-1 (human natural killer-1, also 
known as CD57 and LEU7)59.  
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      CD57 – designated as cluster of differentiation is defined as a terminally 
sulfated carbohydrate epitope. It was first described in 1981 on human natural 
killer cell (HNK) and it is also called as NK-1, LEU-7, or L2. This is  a 
glycoepitope composed of GlcA attached in 1-3 linkage to a terminal galactose. 
This is synthesized by specific glucuronosyltransferases on terminal units of N-
glycans. Glucuronylation is followed by 3-O-sulfation of the GlcA by one or 
more specific sulfotransferases. It is also described as O-glycans of 
glycoproteins, proteoglycans and glycolipids60. 
 
Figure 2: Structure of the B3GAT1 gene 
 
Importance of CD 57: 
CD57 is typically expressed by the natural killer cells and the cytotoxic 
CD8+ lymphocytes. In cytotoxic CD8+ lymphocytes, it is used as a marker of 
replicative senescence whereas in NK cells, CD57 expression is used to identify 
the peripheral NK cells maturation. NK cells expressing CD57 are highly 
cytotoxic and the presences of these cells are beneficial in certain non-
communicable diseases and cancer. Therefore, it is suggested that CD57 can be 
used as a marker to indicate the immune senescence of the individual61.  
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Since the presence of NK cell is an integral part of the tumour 
microenvironment and in the control process of the tumour, the expression of 
CD57 helps in evaluating the immune status of the patient61. 
 
Figure 3: NK cells expressing CD57 antigen. 
CD 57 expression and cancer: 
CD57 and CD8+ lymphocytes are accumulated in individuals in various 
forms of cancer such as renal cell carcinoma, gastric carcinoma, melanoma, 
multiple myeloma, Hodgkin’s lymphoma, acute and chronic myeloid leukemia, 
and chronic lymphocytic leukemia. High expression of CD57 tumour cells are 
seen in cancer patients that has been attributed to less severity of the diseases and 
better outcomes 62. 
This could be due to the immunosurveilance of the individual and the 
cytotoxic behavior of the NK cells. NK cells secrete the most important cytokines 
IFN-gamma after the stimulation of IL12/IL2, associated with the long term 
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survival of the patient. This suggests that heterogeneous group of NK cells 
consisting of CD57 subsets is useful in eliminating the neoplastic cells 62. 
According to Turkseven and Oygur (2010), in oral squamous cell 
carcinoma, low density of tumour infiltrating CD57 cells (NK Cells) and the higher 
expression of TNF- alpha are correlated with high aggressive behavior of the lesion 
and low survival rate63. 
According to Sorskaar et al (1989), in acute lymphoblastic leukemia, 
increased numbers of CD57 and decreased NK cell activity and CD16 NK cells 
in bone marrow associated with complete remission64. 
Ortac et al. (2002) studies showed that the absence or low number of 
CD57 NK cells in the tumor tissue is associated with the relapse of Hodgkin’s 
lymphoma and higher numbers of intratumoral CD57 NK cells are associated 
with no relapse and survival free in pediatric cases of non-hodgkin’s 
lymphoma65. 
Vaquero et al. (2003) studies revealed that NK cells can infiltrate the 
melanoma, lung, breast, and renal carcinomas; but suggested that there is no 
correlation between numbers of infiltrating CD57 NK cells and apoptosis of 
malignant cells 66. 
Lv et al. (2011) in his study showed that, tumour infiltrating CD57 NK 
cells in esophageal squamous cell carcinoma are positively associated with 
increased survival over 80 months 67. 
Villegas et al. (2002) studies demonstrated that tumor infiltrating CD57 
NK cells in squamous cell lung Carcinoma have positive correlation with the 
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survival rate. They showed that these patients have an increased survival rate of 2 
years after surgery68. 
Thus, these studies proved that CD57 is a very valuable marker of NK 
cell maturation and identifying the cells with potent cytotoxic potential towards 
tumour cells. 
                      Proliferating cell nuclear antigen (PCNA) 
Gene profile:  
 Identity of the Gene       :  PCNA-proliferating cell nuclear antigen 
Location of the gene :  20p12.3 
Proliferating cell nuclear antigen (PCNA) is a well-established protein 
seen in all eukaryotic and archae species necessary for cell division and DNA 
replication. The other functions of PCNA are DNA repair, Chromatin 
remodeling, cohesion of sister-chromatid and control of cell cycle. Proliferating 
cell nuclear antigen (PCNA) is a highly characteristic marker for cell 
proliferation 69. 
History: 
           PCNA protein is present on all eukaryotic species from the origin of 
species on earth. Despite of the evolutionary changes in the genetic material, this 
PCNA protein has not undergone any changes in its characteristic structure and 
functions over millions of years69. 
PCNA was discovered before 30 years ago in the patients of systemic 
lupus erythematosus as an antigen. Two years later, some other researchers found 
that 36 kd protein which was expressed during the cell cycle. They named it as 
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“cyclin”. Later, the researchers found out that PCNA is associated with cell 
proliferation as well as in the neoplastic transformation. Finally, it was concluded 
that PCNA and the cyclin are the same protein70. 
PCNA structure: 
 
Figure 4: Three dimensional view of human PCNA – front view 
PCNA belongs to the DNA sliding family DNA polymerase (pol) III b 
subunit and the T4 phage, gene45 protein. The DNA pol III b subunit is a 
homodimer with a pseudo-six-fold symmetry axis in which each monomer was 
composed of three repeated domains. The diameter of a central cavity ring in 
which the double helix of DNA is placed is 3.5 nm  and allows for free and 
smooth sliding movements along the DNA molecule, thus preserving the 
physiological activity of this protein. In this DNA sliding family, PCNA acts as a 
binding site for DNA polymerases and also as a scaffold protein performing 
various functions like, DNA damage repair, chromatin remodeling, DNA 
replication and progression of cell cycle.69,71. 
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In contrast to the DNA pol III b ring with two subunits, the PCNA ring 
consists of three conjoined, identical monomers that are arranged in the form of 
head to tail. In addition, the PCNA possess a protruding C-terminal end which is 
designated as the ‘front’ end whereas the other side is designated as the ‘back’ 
end.  The trimeric PCNA is ring shaped and encircles the DNA. The inner 
surfaces of the ring shaped PCNA  is formed of 12 positively charged a-helices 
which interact with DNA, and the outer layer contains 54 ß-sheets and 
interdomain-connecting loops (IDCL) which makes signiﬁcant contribution to the 
biological activity of PCNA. The IDCL  not only serves to connect the N- and C-
terminal domains of each monomer, but also an important docking site for 
different interacting proteins such as DNA pol d, DNA ligase 1 (DNA lig1), p21, 
DNA-(cytosine-5) methyltransferase  and ﬂap endonuclease (Fen1) 69,71. 
Functions of PCNA: 
a. DNA replication 
     The localization of the PCNA ring on DNA is ideal for allowing this 
protein to function in stabilization, recruitment and dynamic exchange of 
various replication proteins, thus making PCNA a key coordinator of the 
replication process. 
b. Repair 
c. Cell cycle control 
        PCNA interacts with cyclin A–Cdk2 complex and control the cell cycle. 
DNA damaged cells and aging cells leads to increased production of p21 
protein. This p21 protein combines with cyclin dependant kinase (CDK) and 
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blocks the cell cycle from G1 phase to S Phase. This p21 is identified as a 
result of the complex formed by PCNA, Cyclin dependent kinases and 
cyclins71. 
Various studies conducted by using CD57 and PCNA in oral cancers: 
Zain RV et al., in 1995 conducted a study to document the pattern of 
PCNA expression in oral squamous cell carcinoma. In this study, 
immunohistochemical staining of PCNA was done in 36 Oral cancer specimens 
and were investigated by statistical analysis. The results showed that PCNA can 
be used as a valuable marker in the differentiation of the hyperplastic and the 
dysplastic epithelium from the normal epithelium. This study further emphasizes 
that the PCNA expressions are present at the deep, infiltrating margins in 
conventional grading of different grades of OSCC12. 
Kurokawa H et al., in 1995 performed a study to evaluate the expression 
of PCNA in oral squamous cell carcinoma based on histological (mode of 
invasion, differentiation) and clinical findings (TNM clinical stage). This study 
was based upon the immunohistochemical expression of PCNA on various 
histopathological grades of OSCC. Analyzing the data obtained, low level of 
PCNA-positive cells are seen in well differentiated cases and cases with grade 4C 
and 4D revealed high level of PCNA-positive cells. They finally concluded that 
PCNA can demonstrate the proliferating activity of oral squamous cell 
carcinomas, especially in the degree of malignancy72. 
Myong H et al in 2006 had done a study to examine the relationship 
between proliferation markers and the rate of survival in oral squamous cell 
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carcinoma (OSCC) patients. This study was also conducted to determine the 
potentiality of proliferation markers in predicting lymph node metastasis. The 
study was based upon immunohistochemical expression of PCNA and Ki-67. 
Statistical analysis was done by univariate and multivariate analysis. From 
this result, it can be postulated that the cancer staging based on the TNM stage 
was a powerful prognostic variable and Ki-67 had a significant effect on the 
cumulative survival rate73. 
Turkseven MR et al in 2010 performed a study to find out the 
relationship between the biological behaviors of the tumor and the host local 
immune response by assessing the expressions of intratumoral natural killer (NK) 
cells and tumor necrosis factor-alpha (TNF-alpha) in oral squamous cell 
carcinomas. A total of 46 cases of oral squamous cell carcinomas were included 
in this study. The paraffin sections were immunohistochemical treated by 
CD57and TNF-alpha antibodies. The CD57 and TNF-alpha expression were 
analyzed according to the histopathologic grading and clinical staging groups. On 
analyzing the data obtained, low density of CD57+ cells (NK cells) and higher 
expression of TNF- alpha were seen in tumors graded as poor prognostic group 
compared to the cases in good prognostic group. These findings suggested that 
the increased secretion of TNF-alpha are associated with high invasive potential, 
facilitates the tumor invasion and are also responsible for the suppression of NK 
cells. This study finally concluded that because of the increased secretion of 
TNF-alpha, tumor cells are prevented from NK cell attacks and undergo invasion 
due to genetic alterations in the tumor microenvironment63. 
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Watanabe S et al., in 2010 conducted an immunohistochemical study to 
investigate the expression of Ki-67, PCNA and cyclin B1 protein which relied on 
the pattern of cell invasion in OSCC.A total of 39 OSCC specimen and 13 normal 
samples were analyzed. Pearson’s test, Mann Whitney test, Kaplan- Meier 
method & SPPS 11.0 were used as statistical methods. They concluded that Ki-
67, PCNA, & cyclin B1 expression characterize the invasive tumour front that 
leads to better understanding of the behavior of OSCC74. 
Zancope E et al., in 2010 done a study to estimate the population of CD8 
and NK (Natural killer) cells by immunohistochemistry on 70 OSCC and the 
results were analyzed using Cox regression analysis. The results showed that 
higher proportion of Cd8+ cells and NK cell were seen in OSCC indicating the 
lower neoplastic proliferation of the lesions. Therefore, the infiltration of NK 
cells and CD8+ cells reflect the distinctive tumor microenvironments that possess 
a favorable local cytotoxic response against neoplastic cells75. 
Kato K et al., in 2011 conducted a study to examine the expression of 
P53 and PCNA at the invasive front of OSCC by immunohistochemical staining 
and investigated their relationship with the prognosis of the patient. The study 
was conducted on 59 biopsy cases of OSCC and data were analyzed by using 
Mann-Whitney’s U test and Kaplan - Meier method. On analysis, the study 
showed a high labeling index of p53 and PCNA in OSCC and it is associated 
with poor prognosis76. 
Fraga CA et al., in 2012 conducted a study to investigate the detection of 
CD57 inflammatory cells in HNSCC and their association with the overall 
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survival rate. A retrospective and analytical study was performed in 70 patients’ 
specimen with anti CD57. Results were statistically analyzed by bivariate and 
multivariate analysis. The results indicated that predominant infiltration of CD57 
inflammatory cells within the peritumoural stroma of HNSCC indicated a good 
prognosis and also added that high infiltration of inflammatory CD57 cells alone 
should not be considered as an independent prognostic marker in development of 
HNSCC.9  
Iida M et al., in 2014 conducted a study to examine the significance of 
the presence of CD57 cells in peripheral blood from the patients of OSCC. The 
study was done in a total of 43 patients with OSCC by fluorescence-activated cell 
sorting analysis. They interpreted that CD57 cells are significantly increased with 
the clinical stage of the disease. Hence an increase in the CD57 cells is a potent 
valuable prognostic marker in the detection of the aggressiveness of OSCC77. 
Madan M et al., in 2015 performed a study to assess the proliferative 
index in potentially malignant lesions and malignant oral lesions using PCNA 
expression and AgNOR methods. A retrospective study was conducted on 30 
cases of leukoplakia, 15 non-dysplastic, 15 dysplastic and 15 cases of OSCC   for 
immunohistochemical detection of PCNA. The results were analyzed using 
ANOVA, Tukey’s honest significant difference, Pearson correlation. Based on 
these findings it is concluded that AgNOR alone cannot be a valuable parameter 
and PCNA can be used as a useful biomarker in different grades of OSCC14. 
Poosarla CS et al., in 2015 conducted a study to evaluate the expression 
of PCNA in OSCC and to determine whether PCNA can be used an index for 
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clinical aggressiveness in oral premalignancy lesions and OSCC.  This study was 
conducted on a total of 50 blocks that were previously histopathologically 
diagnosed as OSCC. The observed data were analyzed by one way ANOVA test, 
Fischer’s test, and student’s t test. The result showed a steady increase in the 
proliferative index from the normal to various grades of OSCC and therefore, 
PCNA index can be used to assess the cell proliferation and aggressiveness in 
dysplasia and different grades of OSCC78. 
Agarwal R et al., in 2016 performed a study to assess the expression 
of CD57 and to correlate the expression of CD57 with 3 years survival  in 
patients with OSCC. A total of 100 patients of various grades of OSCC were 
included in the study. Further, these 100 patients were divided into two 
groups; group 1 with 50 dead patients and group II with 50 live patients. The 
results were obtained by using the spearman’s correlation coefficient and 
student’s unpaired t-test. They concluded that there is a significant correlation 
exists in between the CD57 and the prognosis of the patients2. 
Abdul Khadir SN et al., in 2016 conducted a study to evaluate PCNA 
and P53 expression in oral squamous cell carcinoma by immunohistochemistry. 
This was a retrospective study done on archival paraffin-embedded tissue blocks 
of 20 patients that were histopathologically diagnosed as oral squamous cell 
carcinoma. These archival blocks were analyzed by using the antibodies against 
P53 and PCNA. The results were analyzed by using Balanced ANOVA test and 
chi- square test. From the results, it was concluded that PCNA and P53 
expression in OSCC has a prognostic significance and are associated with 
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biologically aggressive tumors. Hence PCNA can be used as a good indicator 
for detecting the aggressiveness of the lesion in all grades of OSCC79. 
In 2016 Taghavi N et al., conducted a study to evaluate the prognostic 
significance of CD 57, CD16 and TGF-β expression in OSCC. This is a 
retrospective study conducted on 57 patients that were primarily diagnosed as 
oral squamous cell carcinoma. Immunohistochemical examination of CD 57, 
CD 16 & TGF-β were done in 57 cases of histopathologically diagnosed OSCC. 
The relationship between marker’s expression and clinicopathological data were 
analysed using bivariate and multivariate analysis. On analyzing the data 
obtained, CD57 expression and mode of invasion were concluded to be 
independent prognostic factors of survival in OSCC patients80. 
Fang J et al., in 2017 conducted a study to evaluate the importance of 
tumor infiltrating immune cell in patients with oral squamous cell carcinoma. 
This study was conducted in 78 OSCC patients with a follow up of 2 years. 
Immunohistochemical expression of T-bet, CD8, CD4, CD57and CD68 positive 
cells were assessed and the experimental data  were analyzed by using  Chi-
square test, univariate and multivariate COX analysis. The predictive potential 
of immune cells for survival of OSCC patients was determined by using ROC 
(receiving operator characteristics) and AUC (area under curve) analysis. They 
concluded that the infiltration of CD57 and CD8 expression in the tumor stroma 
was associated with the status of lymphnode involvement and also predicts the 
survival of OSCC patients independently 81. 
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Ahmed S et al., in 2017 performed a study to compare the expression of 
AgNORs with PCNA in Oral squamous cell carcinoma (OSCC) and also to assess 
the reliability between PCNA and AgNOR. Previously confirmed 30 cases of oral 
squamous cell carcinomas were taken for the study and statistical analysis was done 
by ANOVA test. On analyzing the data obtained, PCNA expression and AgNOR 
count was found to be increased from well-differentiated OSCC followed by 
moderately differentiated and poorly differentiated OSCC. Therefore, they 
concluded that the proliferative activity is more in poorly differentiated OSCC. The 
combination of PCNA with AgNOR count appears to be an effective means of 
identifying the proliferating activity of squamous cell carcinoma82. 
Oliveira Maciel TA et al., in 2017 performed a study to evaluate the 
presence of NK cells and CD8+ T lymphocytes in lower lip Squamous Cell 
Carcinomas and its correlation with clinico-pathologic parameters. Thirty two 
cases of lower lip SCCs were included in the study for the immunohistochemical 
assessment of NK cells and CD8+ cells. Results were analyzed by Mann-
Whitney test and spearman correlation coefficient. They found that CD57+ and 
CD8+ T cells were more abundant in clinical stages I/II, non-metastatic cases and 
low-grade malignancy tumors. They concluded that the high expression of 
CD57+ and CD8+ cells at the invasion front suggests that they are involved in 
anti-tumor defense83. 
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MATERIALS AND METHODS 
The current study was done in the department of oral pathology and 
microbiology at Sree Mookambika Institute of Dental Sciences in Kulasekharam. 
a. Study design: Cross sectional study. 
b. Approximate total duration of the study: 1 year.  
c. Number of groups to be studied:   Four Groups. 
d. Detailed description of the groups: 
Group1 :  Tissue sections taken from the paraffin embedded blocks 
that are clinically diagnosed and microscopically confirmed 
cases of normal mucosa – (Control group)  
Group 2 :  Tissue sections taken from the paraffin embedded blocks 
that are clinically diagnosed and histopathologically 
confirmed cases of well differentiated squamous cell 
carcinoma (WDSQCC)  
Group 3 :  Tissue sections taken from the paraffin embedded blocks 
that are clinically diagnosed and microscopically confirmed 
cases of moderately differentiated squamous cell carcinoma 
(MDSQCC) 
Group 4 :  Tissue sections taken from the paraffin embedded blocks 
that are clinically diagnosed and microscopically confirmed 
cases of poorly differentiated squamous cell carcinoma 
(PDSQCC) 
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 Hence forth, a total of 40 blocks were included in the study. Three 
sections were taken from each block and each section measured of 3-4 micron 
thickness. One section was stained with the haematoxylin and eosin stain to 
reconfirm the diagnosis while the other two sections were subjected to 
immunohistochemical staining for proliferating cell nuclear antigen (PCNA) and 
CD 57 respectively. 
e. Inclusion criteria:  
 Paraffin embedded blocks of histopathologically diagnosed cases of well 
differentiated squamous cell carcinoma (WDSQCC). 
 Paraffin embedded blocks of histopathologically diagnosed cases of 
moderately differentiated squamous cell carcinoma (MDSQCC). 
 Paraffin embedded blocks of histopathologically diagnosed cases of poorly 
differentiated squamous cell carcinoma (PDSQCC). 
f. Exclusion criteria:  
 Stored Archival blocks in which antigen retrieval could not be done. 
SAMPLING: 
Sample Size,  n = 
4𝑝𝑞
𝑑2
 
n = Sample size 
In reference to the study performed by Watanabe S et al., in 201074, 
The obtained value of p = WHO - HMG = 79.4 
q= 100 - p 
d= 20% of p  
n = Sample size 
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As per this calculation, a total sample of 40 patients was taken, and each 
group contained 10 patients respectively. 
Group 1:  Ten blocks of normal mucosa (n=10) 
Group 2:  Ten blocks of well differentiated squamous cell carcinoma 
(n=10)  
Group 3: Ten blocks of moderately differentiated squamous cell 
carcinoma (n=10). 
Group 4:  Ten blocks of poorly differentiated squamous cell carcinoma 
(n=10) 
g. Sampling Technique: Convenient sampling. 
METHOD / TECHNIQUE / INSTRUMENTS / REAGENTS/ KIT                               
ARMAMENTARIUM 
Apparatus and equipments: 
  Semiautomatic microtome (Spencers, Model no: 1010-SMT-006, India)  
  Microscopic Slide warming table (Science House Brand, India) 
 Tissue flotation water bath (Science House Brand, India) 
 Electronic weighing machine, (Infra Digital Limited, India) 
 pH meter (Hannah instruments, India) 
 Digital  mint timer (Salter, United Kingdom) 
 Pressure cooker (Pigeon, India) 
 Poly-L lysine coated slides (Pathensitu technologies pvt ltd, India) 
 Graduated measuring jars (Borosil Adelab scientific, Australia ) 
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 Graduated measuring Beakers (Borosil Adelab Scientific, Australia) 
 Coplin  glass staining jars (Tru Laboratories, Philippines) 
 Histology IHC Slide carrier (Shpc trading center, India) 
 Volumetric micropipettes (Accupipetes, India) 
 Stirring glass rods (Borosil Adelab scientific, Australia) 
 Microscope Cover glass (Cover slips) (Blue star slides pvt ltd, India) 
 Refrigerator (Electrolux smart series, India) 
 Compound light microscope (labomed, India) 
 Storage cabinet for archival blocks ( India) 
 Sterile gauze 
Other reagents used in immunohistochemistry techniques are: 
 Filtered deionized water (Roshan Industries, India) 
 Ethanol 70%, 80%, 90%, 100% (Shree Krishna Chem enterprises, India ) 
 Hydrochloric acid-1Normal (RFCL limited- Rankem, India)  
 Xylene (Nice chemicals, India) 
 Mayer’s  Hematoxylin (Himedia labs, India)  
Buffers  
1. Antigen retrieval buffer 
                        Sodium citrate buffer (pH 6.0)  
2. Wash buffer : 
                        TRIS- buffer saline (pH-7.6). 
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Antibodies employed in this present study are:  
1. Primary antibody - (Pathensitu technologies pvt ltd, India) 
a. Rabbit Monoclonal PCNA antibody PC10  ( cat#  PR 065) for PCNA 
expression 
b. Mouse  monoclonal  - CD57 antibody (cat # PM 161) for CD57 
expression 
2. Secondary antibody - (Pathensitu technologies pvt ltd, India) 
a. Endogenous block (Hydrogen peroxide block)  
b. Protein block 
c. Horse radish peroxidase  
d. Chromgen DAB (Diamino benzidine tetra hydrochloride) detection 
system 
Schematic representation of immunohistochemistry procedure: 
Tissue sections of 4-5 micron thickness is transferred to poly L-lysine coated slide 
Deparaffinization of tissue section in descending grades of alcohol 
Antigen retrieval using heat induced epitope retrieval methods 
Quenching of endogenous enzymes or blocking using 3% hydrogen peroxide or with 
free avidin 
Blocking of nonspecific binding sites 
Binding of primary antibody 
Binding with biotinylated secondary antibody 
Detection using peroxidases – antiperoxidase methods 
Addition of chromogen substrate usually, Diaminobenzidine tetrachloride 
Counterstaining, dehydrating and cover slipping the slides 
 
c 
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Procedure: 
Sectioning of tissues: 
 Sectioning of tissue was carried out on a rotary semiautomatic microtome of 
4-5 micrometer thickness. The serials of tissue sections were transferred to 
the tissue flotation bath and then onto the Poly L- lysine coated slides. 
Preparation of buffer solutions: 
a) Wash buffer 
TRIS-Sodium chloride buffer 
o TRIS buffer- 0.3g 
o Sodium chloride- 4g 
o Distilled water- 500ml  
o 1 Normal hydrochloric acid- 2 ml     
 The ingredients were mixed and dissolved and the pH is adjusted to 7.6 
with 1M Hydrochloric acid 
b) Antigen retrieval buffer  
Sodium Citrate buffer solution 
o Tris Sodium citrate – 3.04 g 
o Ethylene di amino tetra acetic acid- 0.37g 
o Distilled water – 1000ml 
o 1normal hydrochloric acid- 4ml 
 The ingredients were dissolved and standardized with pH meter and the 
pH is adjusted to 9.0 
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Deparaffinization /Dehydration: 
 The slides were dewaxed by heating at 60oc for 60 minutes followed by 
deparaffinization in xylene for half an hour. The slides were then  kept in 
absolute alcohol for ten minutes followed by descending grades of alcohol [ 90%, 
80%, and 70%]  each for 10 minutes. The sections were then washed in distilled 
water for five minutes 
Antigen retrieval method: 
 The slides with the tissue sections were put in sodium citrate buffer 
solution (pH 9.0) and kept in microwave oven for 10minutes at high power and 
allowed it to cool for few minutes. The same steps were repeated for another 8 
minutes, 6 minutes and 5 minutes respectively. After these steps were done, the 
slides were cooled for 30 minutes.  
              Slides were washed in distilled water for 5 minutes and dried it 
completely. The slides are then immersed in wash buffer for five minutes. 
Blocking of endogenous peroxidase enzyme: 
 The slides were treated with hydrogen peroxide for ten minutes to block 
the endogenous peroxidase enzyme activity and washed with wash buffer for five 
minutes. 
Protein block: 
 The slides were then subjected to one drop of protein block and kept for 
ten minutes and the slides were blotted dry with the tissue paper. After this 
procedure, no wash buffer was used. 
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Incubation with primary antibody: 
 The tissue sections were then covered with primary antibody and incubated 
for one hour. For PCNA expression, rabbit monoclonal PCNA antibody PC10 and 
for CD57 expression, mouse monoclonal - CD57 antibody was used. The sections 
were then washed in two changes of wash buffer for five minutes each. The excess 
solution were wiped with the tissue paper. 
Incubated with secondary antibody: 
 A drop of horseradish peroxide secondary antibody was added on the 
sections and incubated for thirty minutes. The sections were then washed in two 
changes of wash buffer for five minutes each. The slides were wiped off to 
remove the excess wash buffer. 
Addition of chromogen substrate: 
 Freshly prepared chromogen substrate was added on to the tissue sections 
and kept for five minutes. Slides were washed in distilled water for five minutes. 
Counter staining: 
 The slides were counterstained with Mayer’s haematoxylin and rinsed in 
tap water for the process of bluing. 
Mounting  
  The tissue sections were mounted with DPX.  (Distrene polystyrene xylene)  
Controls  
 Controls are necessary for validation of immunohistochemical staining 
results. 
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a. Positive tissue control: 
     A positive control includes tissue types that express the protein of interest. 
This indicates that the procedure is working and optimized. 
b. Negative tissue control 
 Includes a tissue type in which the protein of interest is not expressed. 
This is to check for nonspecific signal and false positive results. In this study, 
tissues which were not stained properly with the omission of primary antibody 
were considered as a negative control. 
Evaluation 
 Cells are considered as positive for CD57 if there are intracytoplasmic 
DAB staining (chromogenic colour)  
 Cells are considered as positive for PCNA staining when the nucleus 
of the highly mitotic cells stains up in light brown colour.   
Parameters to be studied: 
CD57 labelling index 
CD57 was evaluated by counting the number of cells stained positively. A 
total of 1000 tumour cells were counted. CD57 labelling index was calculated 
according to Stelin S et al (2009)84. 
 CD57 labelling index =  
𝑻𝒐𝒕𝒂𝒍 𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆𝒍𝒚 𝒔𝒕𝒂𝒊𝒏𝒆𝒅 𝒄𝒆𝒍𝒍𝒔
𝟏𝟎𝟎𝟎
𝒙𝟏𝟎𝟎 
PCNA index 
              PCNA positive cells were obtained by counting from a minimum of 
1000 tumor cells from 3 microscopic fields. The procedure will be repeated for 
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two times in order to eliminate the intraexaminer variability and the mean value 
was taken. PCNA index was calculated by the criteria given by Poosarla CS et al 
(2015)78. 
PCNA labelling index =  
𝑻𝒐𝒕𝒂𝒍 𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇  𝒑𝒐𝒔𝒊𝒕𝒊𝒗𝒆𝒍𝒚 𝒔𝒕𝒂𝒊𝒏𝒆𝒅 𝒄𝒆𝒍𝒍𝒔
𝟏𝟎𝟎𝟎
𝒙𝟏𝟎𝟎 
Statistical method of analysis: 
 The data obtained in this study were analyzed using the SPSS version 
16.0 (Statistical package for social science) software. To compare and correlate 
the expression of CD57 and PCNA expression in oral squamous cell carcinoma, 
mean, standard deviation and Pearson’s correlation coefficient test were used. 
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CP 11: Photomicrograph showing histology of normal mucosa                                           
(H&E staining; x100) 
 
 
CP 12: Photomicrograph showing expression of PCNA in normal mucosa                     
(IHC staining; x400) 
 
 
CP 13: Photomicrograph showing expression of CD57 in normal mucosa                             
(IHC staining; x400) 
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CP 14: Photomicrograph showing histopathology of WDSQCC (H&E staining; x100) 
 
 
CP 15: Photomicrograph showing expression of PCNA in WDSQCC (IHC staining; x400) 
 
 
CP 16: Photomicrograph showing expression of CD57 in WDSQCC (IHC staining; x400) 
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CP 17: Photomicrograph showing histopathology of MDSQCC (H&E staining; x100) 
 
 
CP 18: Photomicrograph showing expression of PCNA in MDSQCC (IHC staining; x400) 
 
 
CP 19: Photomicrograph showing expression of CD57 in MDSQCC (IHC staining; x400) 
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CP 20: Photomicrograph showing histopathology of PDSQCC (H& E staining; x100) 
 
 
CP 21: Photomicrograph showing expression of PCNA in PDSQCC (IHC staining; x400) 
 
 
CP 22: Photomicrograph showing expression of CD57 in PDSQCC (IHC staining; x400) 
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RESULTS AND OBSERVATIONS 
The current study was done in the department of oral pathology and 
microbiology at Sree Mookambika Institute of Dental Sciences in Kulasekharam. 
In the present study, the immunohistochemical expression of PCNA and CD57 
was analyzed in different histopathological grades of oral squamous cell 
carcinoma. A total of forty samples were included in the study.  The control 
group consisted of 10 samples of normal mucosa (Group 1) and the study group 
consisted of 10 samples each of well differentiated (Group 2; WDSQCC), 
moderately differentiated (Group 3; MDSQCC), and poorly differentiated (Group 
4; PDSQCC), squamous cell carcinomas. PCNA and CD57 staining was done 
according to manufacturer’s protocol and the stained slides were observed under 
light microscope. 
In this study, the age range for samples in the study groups were 39-72 
years, 53-75 years and 35-70 years with a mean age of 56.79 years, 61.4 years 
and 55.7 years in well, moderate and poorly differentiated squamous cell 
carcinomas respectively. There was a male predilection in the ratio of 4:1 and 3:2 
in well and moderately differentiated cases whereas equal sex predilection in the 
ratio of 1:1 was noticed in poorly differentiated squamous cell carcinoma. 
Documentation of the associated deleterious habits and common site of the lesion 
showed tobacco and betel chewing as the most prevalent cause and buccal 
mucosa as the most favorable site in all the three histopathological grades of 
squamous cell carcinoma.  
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Estimation of PCNA and CD57 were evaluated by the positive and 
negative staining of cells.  Cells were considered as positive for CD57 if there 
was intra-cytoplasmic DAB staining (Chromogenic colour). Cells were 
considered positive for PCNA, when the nuclei of the highly mitotic cells stain as 
light brown in colour. The counts were performed by a single examiner in three 
different high power fields for both CD57 and PCNA. The counting was done 
twice in the same field to eliminate intra-observer variability. A total of 1000 
cells from three different high power fields were counted and the number of 
positive cells was noted.  The results were interpreted in terms of percentage 
positivity and expressed as labelling index (LI).  
The results obtained were subjected to statistical analysis by using 
statistical package for social sciences (SPSS 16.0) software. Analysis of data 
between the groups was done by using ANOVA (Post hoc) followed by Dunnet t 
test. Correlation of PCNA and CD57 between the groups was done with Pearson 
correlation. P-value less than 0.05 (p<0.05) was considered statically significant.  
The mean value of PCNA labelling index was 26.19±1.25, 45.88±2.20, 
59.38±1.04, and 72.77±4.35 in normal mucosa, well differentiated OSCC, 
moderately differentiated OSCC and poorly differentiated OSCC respectively. 
Multiple Comparison of expression of PCNA index between the study groups of 
WDSQCC, MDSQCC and PDSQCC was statistically highly significant with a p-
value of 0.001. Comparison of expression of mean labelling index of PCNA 
between the study groups (WDSQCC, MDSQCC and PDSQCC) and the control 
group (normal mucosa) was also statistically highly significant with a p-value of 
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0.001. The PCNA labelling index was least in normal mucosa and increased in 
well differentiated OSCC followed by moderately differentiated OSCC and the 
highest was noted in poorly differentiated OSCC. These findings indicated that 
the proliferation of cells increased as the grades of OSCC increased. 
Similarly the mean value of CD57 labelling index was 2.91±0.82, 
16.63±2.33, 7.09±1.41 and 5.53±1.20 in normal mucosa, well differentiated 
OSCC, moderately differentiated OSCC and poorly differentiated OSCC 
respectively.  Multiple comparison of expression of CD57 labelling index 
between the study groups of WDSQCC, MDSQCC and PDSQCC was 
statistically highly significant with a p-value of 0.001. Comparison of expression 
of mean labelling index of CD57 between the study groups WDSQCC, 
MDSQCC and PDSQCC with that of the control group (normal mucosa) was also 
statistically highly significant with a p-value of 0.001. The CD57 labelling index 
was least in normal mucosa and highest in well differentiated OSCC.  The CD57 
labelling index was decreased in moderately differentiated OSCC followed by 
poorly differentiated OSCC when compared with well differentiated OSCC but 
the mean values were higher than that of normal mucosa. These findings 
indicated that the natural killer cells or immune status of the individual decreases 
as the grades of OSCC increases. 
In the present study on correlation of mean labelling index of PCNA and 
CD57, the Pearson correlation coefficient value within the groups were found not 
to be correlated which was statistically not significant (p>0.05) whereas the 
values were significant when compared between the groups (p<0.05).   
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Table-1: Mean labelling index of PCNA in different groups 
Groups Description 
PCNA index 
(MEAN±SD) 
Group I Normal Mucosa 26.19±1.25 
Group II 
Well differentiated squamous cell carcinoma 
(WDSQCC) 
45.88±2.20 
Group III 
Moderately differentiated squamous cell 
carcinoma (MDSQCC) 
59.38±1.04 
Group IV 
Poorly differentiated squamous cell carcinoma 
(PDSQCC) 
72.77±4.35 
 
Table-2: Comparison of mean labelling index of PCNA in normal mucosa with   
other groups 
Groups PCNA index (MEAN±SD) p value 
Normal mucosa 26.19±1.25  
WDSQCC 45.88±2.20* 0.001 
MDSQCC 59.38±1.04* 0.001 
PDSQCC 72.77±4.35* 0.001 
(*p<0.05 significant when normal mucosa compared with other groups) 
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Table-3: Comparison of mean labelling index of PCNA in WDSQCC with other 
groups 
Groups PCNA index (MEAN±SD) p value 
Normal mucosa 26.19±1.25* 0.001 
WDSQCC 45.88±2.20  
MDSQCC 59.38±1.04* 0.001 
PDSQCC 72.77±4.35* 0.001 
(*p<0.05 significant when WDSQCC compared with other groups) 
 
Table-4: Comparison of mean labelling index of PCNA in MDSQCC with other 
groups 
Groups PCNA index (MEAN±SD) p value 
Normal mucosa 26.19±1.25* 0.001 
WDSQCC 45.88±2.20* 0.001 
MDSQCC 59.38±1.04  
PDSQCC 72.77±4.35* 0.001 
(*p<0.05 significant when MDSQCC compared with other groups) 
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Table-5: Comparison of mean labelling index of PCNA in PDSQCC with other 
groups 
Groups PCNA index (MEAN±SD) p value 
Normal mucosa 26.19±1.25* 0.001 
WDSQCC 45.88±2.20* 0.001 
MDSQCC 59.38±1.04* 0.001 
PDSQCC 72.77±4.35  
(*p<0.05 significant when PDSQCC compared with other groups) 
 
Table-6: Multiple Comparison of mean labelling index of PCNA between the 
groups 
Groups PCNA index (MEAN±SD) 
Normal mucosa 26.19±1.25 
WDSQCC 45.88±2.20* 
MDSQCC 59.38±1.04*,# 
PDSQCC 72.77±4.35*,#,$ 
(*p<0.05 significant when normal mucosa compared with other groups, #p<0.05 
significant when WDSQCC compared with other groups, $p<0.05 significant when 
MDSQCC compared with other groups) 
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Table-7: Mean labelling index of CD 57 in different groups 
Groups Description 
Labeling index 
(MEAN±SD) 
Group I Normal Mucosa 2.91±0.82 
Group II 
Well differentiated squamous cell 
carcinoma (WDSQCC) 
16.63±2.33 
Group III 
Moderately differentiated squamous cell 
carcinoma (MDSQCC) 
7.09±1.41 
Group IV 
Poorly differentiated squamous cell 
carcinoma (PDSQCC) 
5.53±1.20 
 
Table-8: Comparison of mean labelling index of CD 57 in normal mucosa with 
other groups 
Groups 
Labeling index 
(MEAN±SD) 
p value 
Normal mucosa 2.91±0.82  
WDSQCC 16.63±2.33* 0.001 
MDSQCC 7.09±1.41* 0.001 
PDSQCC 5.53±1.20* 0.001 
(*p<0.05 significant when normal mucosa compared with other groups) 
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Table-9: Comparison of mean labelling index of CD 57 in WDSQCC with other 
groups 
Groups Labeling index (MEAN±SD) p value 
Normal mucosa 2.91±0.82* 0.001 
WDSQCC 16.63±2.33  
MDSQCC 7.09±1.41* 0.001 
PDSQCC 5.53±1.20* 0.001 
(*p<0.05 significant when WDSQCC compared with other groups) 
 
Table-10: Comparison of mean labelling index of CD 57 in MDSQCC with 
other groups 
Groups Labelling index (MEAN±SD) p value 
Normal mucosa 2.91±0.82* 0.001 
WDSQCC 16.63±2.33* 0.001 
MDSQCC 7.09±1.41  
PDSQCC 5.53±1.20* 0.001 
(*p<0.05 significant when MDSQCC compared with other groups) 
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Table-11: Comparison of mean labelling index of CD 57 in PDSQCC with other 
groups 
Groups Labelling index (MEAN±SD) p value 
Normal mucosa 2.91±0.82* 0.001 
WDSQCC 16.63±2.33* 0.001 
MDSQCC 7.09±1.41* 0.001 
PDSQCC 5.53±1.20  
(*p<0.05 significant when PDSQCC compared with other groups) 
 
Table-12: Multiple Comparison of mean labelling index of CD 57 between the 
groups 
Groups CD 57 index (MEAN±SD) 
Normal mucosa 2.91±0.82 
WDSQCC 16.63±2.33* 
MDSQCC 7.09±1.41*,# 
PDSQCC 5.53±1.20*,#,$ 
(*p<0.05 significant when compared normal mucosa with other groups, #p<0.05 
significant when WDSQCC compared with other groups, $p<0.05 significant 
MDSQCC compared with other groups) 
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Table-13: Correlation of PCNA labelling index with CD 57 labelling index 
within the groups 
Groups 
 
 
Correlation 
PCNA 
CD 57 labelling 
index 
(r value) 
p value 
Normal mucosa -0.43 0.20 
WDSQCC -0.43 0.21 
MDSQCC -0.58 0.07 
PDSQCC -0.59 0.06 
 
Table-14: Correlation of PCNA labelling index with CD 57 labelling index 
between the groups 
Correlation 
PCNA 
CD 57 Labelling index (r value) 
p value 
Normal 
mucosa 
WDSQCC MDSQCC PDSQCC 
Normal mucosa -0.43 -0.67* -0.78* -0.89* 0.04 
WDSQCC -0.64* -0.43 -0.76* -0.92* 0.03 
MDSQCC -0.68* -0.71* -0.58 -0.96* 0.03 
PDSQCC -0.75* -0.74* 0.81* -0.59 0.03 
(*p<0.05 significant correlated between the groups) 
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                Graph-1: Mean age distribution in different grades of OSCC 
 
 
                      Graph-2: Ratio of sex in different grades of OSCC 
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Graph-3: Comparison of mean labelling index of PCNA between the groups 
 
 
Graph-4: Comparison of mean labelling index of CD57 between the groups. 
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Graph-5: Comparative correlation of PCNA labelling index with CD57 
labelling index within the groups 
 
 
Graph-6: Correlation of PCNA labelling index with CD57 labelling index 
between the groups 
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DISCUSSION 
Oral cancer is the most common malignancy and it is the sixth most 
common cancer in the world85. The development of oral cancer is a multistep 
process that requires around four to seven events for the genetic changes to occur. 
These genetic alterations involve the classic hallmarks of malignancy and also 
undergo immortalization. As a result, the cells undergo behavioral and metabolic 
changes leading to uncontrolled proliferation7. 
Early diagnosis is vital as it reduces the severity and complications of the 
diseases but it also helps in planning of the treatment and prognosis. Recent 
advances in genomics and proteomics identify the diseases by using gene or 
protein profiles. These advanced techniques use a multiple panel of markers 
which helps in accurate identification of diseased status of the individual. 
Recently, an immunohistochemical study also involves the uses of multiple 
markers as an aid in the accurate diagnosis of the diseases84. 
PCNA is a characteristic marker for cell proliferation. These markers are 
helpful in identifying the aggressive nature of the lesion. These markers play a 
vital role in DNA replication, chromatin remodeling, control of cell cycle and 
DNA repair. Mutation of the PCNA gene is seen in various types of cancers76. 
Lee JJ et al (2005) showed that PCNA was    a good indicator for the aggressive 
nature and the malignant potential of the lesion86. Tsuji et al (1992) showed that 
proliferation of tumour cells was an important predictor of the aggressiveness of 
the lesion and PCNA is an important protein which is expressed during the 
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process of proliferation and immunohistochemical detection of this protein helps 
to evaluate the proliferative capacity of tumour in oral squamous cell 
carcinoma87. 
Only few markers are useful in predicting the prognosis of the disease. 
Nagpal M (2016) concluded that the proliferative markers cannot be used as an 
independent marker for evaluating the prognosis of the diseases as these markers 
are useful indicators of the clinical aggressive nature of the lesion88. 
CD8+ cytotoxic lymphocytes mainly acts on the virus infected cells and 
tumour cells. Natural killer cell which is a subset of small population of T–cell, is 
an important effectors innate and adaptive immunity. These natural killer cells act 
without any prior activation. These cells identify the tumour cells by the lack of 
expression of class I major histocompatibility complex (MHC) and kill them by 
either secreting interferon-gamma or through perforin-granzyme activity58. CD 
57 expression is most prominently seen in the highly matured NK cell. CD57 
exhibit more potent immune response functions and inhibit the tumour 
development 80. According to Carlos Alberto et al (2002), high density of CD57 
cell infiltration alone was not considered as an independent prognostic marker for 
head and neck squamous cell carcinoma.9. 
Hence, in the present study, we use both PCNA and CD57 and analyzed 
the expression in different grades of oral squamous cell carcinoma. After a 
thorough data search, this study is the first documented study where PCNA and 
CD57 were used to find out the aggressiveness of the lesion and the immune 
status of the individual. 
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In the present study, we evaluated the immunohistochemical expression 
of PCNA in 10 cases each of well differentiated squamous cell carcinoma, 
moderately differentiated squamous cell carcinoma and poorly differentiated 
squamous cell carcinoma. Normal oral mucosa was considered as the control 
group. PCNA positive cells were identified by the light brown granular staining 
of nucleus. PCNA index was calculated according to the criteria given by 
Poosarla et al (2015)78. The PCNA index was 26.19±1.25, 45.88±2.20, 
59.38±1.04 and 72.77±4.35 for normal mucosa, WDSQCC, MDSQCC and 
PDSQCC respectively. Higher expression of PCNA was found in poorly 
differentiated squamous cell carcinoma. The intensity of staining and the number 
of positive PCNA cells were increased gradually from Group I to Group IV. This 
result was in accordance with the studies conducted by Abdul Khadir et al 
(2010)79, Madan M et al (2015)14, Poosarla CS et al (2015)78, Roopavathi Keshav 
et al (2015)89, Ahamed et al (2017)82 (Table 1, 2, 3, 4, 5, 6 & Graph 3). 
 In 1993, Shin DM et al., studied the PCNA expression in oral squamous 
cell carcinoma. They showed that the PCNA was increased to about four to ten 
times in squamous cell carcinoma when compared to the normal epithelium90.  
Girod et al (1994) in their study found that there is a steady increase of 
PCNA expression from normal mucosa to well differentiated squamous cell 
carcinoma followed by moderately differentiated squamous cell carcinoma91. 
Zain et al (1995) opined that PCNA is good marker in differentiating normal 
epithelium and dysplastic epithelium12. 
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Abdul Khadir et al (2010) from their study suggested that the expression of 
PCNA was a good indicator for the aggressiveness of the lesion79. Madan M et al 
(2015) showed that PCNA was a good marker in differentiating normal epithelium 
from oral squamous cell carcinoma14. Poosarla CS et al (2015) showed that 
proliferation of cells were increased from normal to premalignant lesions and to 
oral squamous cell carcinoma and they concluded that PCNA marker was useful in 
predicting the aggressiveness of the lesion78. Keshav R et al (2015) studied the 
expression of PCNA in oral submucous fibrosis and concluded that PCNA was an 
indicator of the biological behavior of the lesion89. Ahamed et al (2017) opined that 
proliferation of cells was more in poorly differentiated followed by moderately 
differentiated squamous cell carcinoma and well differentiated squamous cell 
carcinoma81. The current study also showed a steady increase of PCNA expression 
when the grades of the oral squamous cell carcinoma is increased. 
 In the present study, the expression of CD57 labelling index was 
2.91±0.82, 16.63±2.33, 7.09±1.41 and 5.53±1.20 in normal mucosa, WDSQCC, 
MDSQCC and PDSQCC respectively. It was found that the CD57 expression 
was increased from the normal mucosa to well differentiated squamous cell 
carcinoma. According to Karpathiou et al (2017), in head and neck tumours, there 
is a dense infiltration of cytotoxic T lymphocytes, NK cells and dendritic cells. 
These cells are increased in number in order to kill the tumour cells92. Therefore, 
in well differentiated SQCC the CD57 expression was increased. In moderately 
differentiated and poorly differentiated SQCC, the CD57 expression was 
decreased compared to well differentiated SQCC but increased in comparison 
with the normal mucosa. This clearly indicates that rich infiltration of natural 
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killer cells is associated with increased survival of the patient. Lack of these cells 
in moderately differentiated and poorly differentiated squamous cell carcinoma 
indicates the poor survival rate. 
Fang et al (2017) opined that a high CD57 expression in the early stage of 
the diseases and found that strong CD57 expression in oral squamous cell 
carcinoma could be an independent marker for longer survival81. Agarwal R et al 
(2016) opined that CD57 mean labelling index was higher in alive patients 
(10.67) than dead patients (3.67). This study concluded that higher CD57 
labelling index had a significant correlation with the status of the life2. Taghavi et 
al (2015) indicated that high CD57 expression was associated with longer overall 
survival of the patient80. The present study also showed a high CD57 expression 
in well differentiated squamous cell carcinoma and lower CD57 expression in 
moderately differentiated and poorly differentiated squamous cell carcinomas that 
are associated with the decreased survival of the patient. 
Iida et al (2014) showed that increased CD57+ T-cells infiltration in the 
tumour microenvironment was a potent prognostic marker for OSCC77.  Zancope 
et al (2010) showed that infiltration of NK cells (CD57) and CD8+ cells in the 
tumour microenvironment reflected a favorable cytotoxic immune response 
against malignant cells75. These findings were in accordance with the present 
study interpreting that high CD57 expression in well differentiated squamous cell 
carcinoma will have a better prognosis whereas low expression of CD57 in 
moderately differentiated followed by poorly differentiated squamous cell 
carcinoma have poor prognosis. (Tables 7, 8, 9, 10, 11, 12 & Graph 4) 
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 In the present study, correlation of PCNA and CD57 labelling index 
within the groups are not significant (Table 13 & Graph 5) But correlation of 
PCNA and CD57 was found to be significant between the groups (Table 14 & 
Graph 6).  PCNA and CD57 are found to be good indicators of aggressive nature 
of the lesion and the immune status of the patient respectively. The combination 
of PCNA and CD57 were found to be effective in identifying the patients with 
good or poor survival rate and thereby it helps in planning of the treatment 
modalities. 
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SUMMARY AND CONCLUSION 
The current study was performed in the department of oral pathology and 
microbiology at Sree Mookambika Institute of Dental Sciences in Kulasekharam. 
In the present study, a total of 40 samples were included. 10 samples each of 
WDSQCC, MDSQCC and PDSQCC constituted the study group whereas 10 
samples of normal mucosa made up the control group. 
In this study, PCNA and CD57 markers were used. PCNA is a well-known 
proliferative marker used to identify the aggressiveness or the biological behavior 
of the lesion. CD57 was used to determine the immune status of the patient. 
The primary aim of this study was to assess the expression of PCNA and 
CD57 in different grades of oral squamous cell carcinoma. An 
immunohistochemical study was carried out by using the primary antibodies anti-
PCNA and anti-CD57 according to the manufacture’s protocol. Positively stained 
cells were counted in 1000 tumour cells and the labelling index of PCNA and 
CD57 were determined. The results were analyzed by using Anova (Post hoc) 
followed by Dunnet t-test between the groups. Comparison of PCNA and CD57 
was done by Pearson correlation coefficient test. 
Highly significant increase in the PCNA labelling index was seen from 
normal mucosa to WDSQCC, followed by MDSQCC and PDSQCC. Maximum 
proliferative index was noted in PDSQCC. Similarly, highly significant decrease 
in CD57 labelling index was seen from WDSQCC followed by MDSQCC and 
PDSQCC. Maximum CD57 index was noted in WDSQCC. 
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On correlation with Pearson correlation coefficient test, PCNA and CD57 
were found to be correlated between the groups. This clearly indicates that PCNA 
and CD57 are related to each other in different grades of oral squamous cell 
carcinoma. 
It was concluded that as the grades of oral squamous cell carcinoma 
increases, the aggressive nature of the lesion increases and the immune status of 
the patient is decreased. Hence forth, the combination of PCNA and CD57 can be 
used as valuable markers to detect the malignant potential of the lesion and also 
to determine the survival rate of the patient wherein which it helps in the 
stratification of patient for planning of treatment modalities. 
Scope for future:  
               Curing of cancer can be possible with the advancement of cancer 
immunotherapy. Recently, introduction of monoclonal antibodies (mAbs), 
adoptive cancer therapy, cancer vaccines and immune checkpoint therapy have 
replaced the traditional cancer therapy. Recognition and stratification of the 
patient will provide a key factor for the success of treatment. Early identification 
of the disease will also improve the survival rate of the patient.  
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2 50 M Right buccal mucosa - 26.4 1.7 
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4 53 M Left buccal mucosa - 25.6 2.9 
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4 52 F Left buccal mucosa Betel nut chewing 68 4.7 
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